Related Experiment Videos

Nuclear transcription factor-kappaB as a target for cancer drug development

A Garg1, B B Aggarwal

  • 1Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Leukemia
|June 1, 2002
PubMed

Insights

Nuclear factor kappa B (NF-kappaB) is crucial in diseases like cancer and inflammation. This review explores NF-kappaB

Area of Science:

  • Molecular Biology
  • Immunology
  • Oncology

Background:

  • Nuclear factor kappa B (NF-kappaB) is a ubiquitous transcription factor family.
  • Its discovery in 1986 opened avenues for understanding numerous diseases.
  • NF-kappaB plays a significant role in inflammation, immune responses, and various pathological conditions.

Purpose of the Study:

  • To review current knowledge on NF-kappaB.
  • To elucidate NF-kappaB activation mechanisms and target genes.
  • To explore NF-kappaB's role in cancer and strategies for drug development.

Main Methods:

  • Literature review of NF-kappaB research.
  • Analysis of NF-kappaB activation pathways.
  • Examination of NF-kappaB's involvement in oncogenesis.
  • Survey of therapeutic strategies targeting NF-kappaB.

Main Results:

  • NF-kappaB is implicated in a wide spectrum of diseases including cancer, inflammation, and infectious diseases.
  • Diverse signaling pathways regulate NF-kappaB activation.
  • Targeting the NF-kappaB pathway presents a promising strategy for cancer therapy.

Conclusions:

  • NF-kappaB is a critical regulator of cellular processes and a key player in disease pathogenesis.
  • Understanding NF-kappaB activation is vital for developing effective treatments.
  • Targeting NF-kappaB signaling offers potential for novel cancer drug development.

Related Concept Videos